Overview

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast

Status:
Completed

Trial end date:
2020-09-02

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to assess the progression-free survival (PFS) of oral veliparib in combination with TMZ or in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in subjects with BRCA1 or BRCA2 mutation and locally recurrent or metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie
AbbVie (prior sponsor, Abbott)

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Dacarbazine
Paclitaxel
Temozolomide
Veliparib